Smith F
Biometrics Department, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA.
J Biopharm Stat. 1996 Mar;6(1):59-67. doi: 10.1080/10543409608835122.
Mixed-model techniques are applied to incomplete longitudinal data from a double-blind, placebo-controlled, parallel-group, high-dose study of tacrine in patients with Alzheimer's disease. The study consisted of a 30-week double-blind treatment period. Patients were randomized to one of four treatment groups. Dosing was initiated at 40 mg/day and increased in increments of 40 mg/day every 6 weeks until the target dose was achieved. If the study medication was not well tolerated or there were significant elevations in alanine aminotransferase, patients were withdrawn from the study. The use of SAS procedure PROC MIXED for the analysis of incomplete longitudinal data is discussed. This approach is used to evaluate disease progression over time and the effect of incremental dose increases of tacrine on changes on the Alzheimer's Disease Assessment Scale-Cognitive subscale.
混合模型技术应用于来自一项他克林治疗阿尔茨海默病患者的双盲、安慰剂对照、平行组、高剂量研究的不完整纵向数据。该研究包括一个为期30周的双盲治疗期。患者被随机分配到四个治疗组之一。给药起始剂量为40毫克/天,每6周以40毫克/天的增量增加,直至达到目标剂量。如果研究药物耐受性不佳或丙氨酸转氨酶显著升高,则将患者退出研究。讨论了使用SAS程序PROC MIXED分析不完整纵向数据的方法。该方法用于评估疾病随时间的进展以及他克林剂量递增对阿尔茨海默病评估量表认知子量表变化的影响。